Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2944)	11/4/2013 4:02:15 PM
From: Zohar_Power	Read Replies (1) \| Respond to of 4474

Biomaven, from the top of my head, I recall that 66% of the PACE patients had been treated with Tasigna (if I am wrong, please correct me). How to tease out, then whether Tasigna "sensitized" Iclusig patients for thrombolytic events, natural thromboloytic events that occur with CML patients (and other risk factors, such as age, triglycerides, hypertension, etc.) and any de-novo effect of Iclusig? Also, the clinical patients for the Tasigna trials were younger and healthier coming off of Gleevec or Sprycell. Some Iclusig patients had been on prior TKI therapy for over a decade!

To: Biomaven who wrote (2944)	11/4/2013 5:06:55 PM
From: GregorioAllegri	Respond to of 4474

Hi In the ASCO presentation on cardiovascular events this summer past, prior nilotinib exposure was greater in the patients with AEs (1.8 years mean) than in the population without AEs (1.2 years mean.) The person presenting thought this was significant. One possibility is that inhibition of abl kinase itself is responsible for the nilotinib effects as it has almost the same use rate as imatinib, but is 10x more potent against abl kinase (which does useful things when not combined with bcr.) Tests on imatinib in mice showed cardiovascular effects when they greatly boosted the dose. A curious thing is that imatinib was proposed for or was in clinical trials for treatment against PAH. May suggest an agonist/antagonist relationship between these two chemically related molecules on some unknown target. ga